Core Viewpoint - Northern Horizon A/S has signed a contract to sell its entire stake in Northern Horizon Capital AS, the management company of Baltic Horizon Fund, to the partners of Grinvest, a private investment company with significant expertise in the commercial real estate market in the Baltics [1][2][4]. Group 1: Transaction Details - The contract for the sale was concluded on August 19, 2025, and involves the transfer of 12,500 shares in Northern Horizon Capital AS to Grinvest's partners [2]. - The ownership distribution will see Antanas Anskaitis acquiring 4,168 shares, while Antanas Danys and Tomas Milašauskas will each acquire 4,166 shares [2]. - The transaction is expected to be completed upon receiving the necessary regulatory approvals [3]. Group 2: Strategic Implications - The sale is described as a strategic decision by Northern Horizon to focus on its core operations and leadership in Nordic social infrastructure investing [4]. - Grinvest aims to leverage its expertise to address the challenges faced by Baltic Horizon Fund over the past five years and is committed to engaging with all stakeholders post-transaction [5]. - The management structure of Baltic Horizon Fund will remain unchanged until the transaction is finalized, ensuring continuity in operations [5]. Group 3: Company Background - Baltic Horizon Fund is a registered contractual public closed-end real estate fund managed by Northern Horizon Capital AS, which holds an Alternative Investment Fund Manager license [8]. - Grinvest is a private investment firm with interests spanning commercial property, transportation, and infrastructure [8].

COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%. Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a strong foundation in place, we are well ...

Anoto Group AB (publ) (“Anoto” or the “Company”) today announces that it has entered into a promissory note (the “Note”) with Achilles Capital AB for a bridge loan in the amount of USD 400,000. The proceeds will be used to support the Company’s working capital requirements as it pursues additional financing, primarily to accelerate the global expansion of its new inq smartpen brand following its highly successful market release. The aim is for the Note to convert into a convertible loan if the Company secur ...

Core Insights - NACON is showcasing its latest games and accessories at Gamescom 2025, following a successful appearance at the Future Games Show [2] - The company is emphasizing its commitment to the racing genre with new titles and accessories [12] Game Releases and Demos - Three major titles highlighted include "Styx: Blade of Greed," set for late 2025 release, featuring gameplay focused on stealth and resource collection [4] - "Hell is Us," an action-adventure game, is scheduled for release on September 4, 2025, and includes a demo available on all platforms [6][5] - "Edge of Memories," a JRPG, is set for release in 2026 and features real-time combat mechanics [9][8] - "Dragonkin: The Banished" has entered early access and is debuting a significant update at Gamescom, introducing new characters and content [10][11] Racing Division Expansion - NACON is expanding its racing division with new accessories and three new racing titles available for hands-on demos [12] - The Revosim racing wheel range is now compatible with consoles, set for release by the end of 2025, designed for serious sim racers [13][14] - "Gear.Club Unlimited 3" is set to launch in late 2025, featuring a variety of environments and over 40 licensed cars [15] - "Endurance Motorsport Series" is designed to reflect the demands of endurance racing and is set for release in 2026 [16] - "RENNSPORT," a next-gen racing simulator, will have console versions expected in Fall 2025 [18][17] Gaming Accessories - NACON is showcasing its latest gaming accessories, including the Revolution X Unlimited controller, which has gained popularity among FPS and action game fans [19] - RIG headsets, particularly the RIG 900 MAX, are highlighted for their audio quality and comfort [20] - Protective cases and travel kits for the Nintendo Switch®2 are also available for purchase [20] Company Overview - NACON, part of the BIGBEN group, was established in 2019 and comprises 16 development studios, focusing on game publishing and premium gaming peripherals [22]

Core Insights - The company reported a strong organic sales growth of 9% in the first half of the year, with an upward revision of the full-year guidance to a range of 6-8% [1][3] - Profitability remains solid despite currency headwinds, with an adjusted EBITDA margin of 37.4%, up by 210 basis points compared to the previous quarter [3] - The company achieved cost synergies at a 100% run rate, indicating improved operational efficiency [3] Sales Performance - Organic sales growth in the Food & Health segment reached 10%, while the Planetary Health segment saw a growth of 9% [3] - Emerging markets experienced a robust organic sales growth of 12%, compared to 8% in developed markets [3] Financial Metrics - Adjusted net profit increased by 23%, reflecting strong financial performance [3] - The company maintained a net interest-bearing debt to EBITDA ratio of 2.1x, following the acquisition of dsm-firmenich's part of the Feed Enzyme Alliance [3] Shareholder Returns - A share buyback program worth EUR 100 million was completed on June 27, enhancing shareholder value [3] - An interim dividend of 2.25 DKK (EUR 0.30) was approved for the first half of 2025 [3] Future Outlook - The company has narrowed its 2025 organic sales growth outlook to 6-8%, with a range of 7-9% excluding exits from certain countries [3] - Long-term financial targets for 2030 have been announced, indicating a strategic focus on growth and investment in unique biosolutions [1][3]

EDF announces the success of its inaugural “Kangaroo” senior multi tranche bond issuance for a nominal amount of AUD 1 billion On 21 August 2025: EDF (BBB positive S&P / Baa1 stable Moody’s / BBB+ negative Fitch) successfully priced its inaugural “Kangaroo” senior bond issuance in 2 tranches for a nominal amount of AUD 1 billion (the “Bonds”): AUD 500 million Bond, with a 10-year maturity and a 5.636% fixed coupon;AUD 500 million Bond, with a 20-year maturity and a 6.627% fixed coupon. This transaction ena ...

Core Insights - The Group's CEO Bjørn Hembre and Interim CFO Edvin Aspli will present the second quarter results on August 21, 2025, at 9:00 Icelandic time [1] - Icelandic Salmon is dual-listed on Euronext Growth in Oslo and NASDAQ First North in Reykjavík, indicating a broad market presence [1] - The Group owns 100% of Arnarlax ehf, a fully integrated farming company in Iceland, controlling the entire value chain from egg to market delivery [1] Company Overview - Icelandic Salmon operates a fully integrated business model, ensuring quality control across all stages of production [1] - The head office of Arnarlax ehf is located in Bíldudalur, Iceland, emphasizing its local operational focus [1] - The Group's commitment to transparency is reflected in its adherence to the Norwegian Securities Trading Act for disclosure requirements [2]

Core Viewpoint - ALK reported a strong Q2 performance with a 12% organic revenue growth and a 41% increase in operating profit, leading to an upgraded full-year revenue outlook [1][6]. Q2 Performance Highlights - Revenue for Q2 2025 reached DKK 1,527 million, reflecting a 12% growth in local currency and an 11% growth in reported currency [3]. - Operating profit (EBIT) for Q2 was DKK 375 million, marking a 41% increase in local currency and a 42% increase in reported currency, with an EBIT margin of 25% [3]. - For H1 2025, revenue totaled DKK 3,049 million, with a consistent 12% growth in both local and reported currencies [3]. Financial Highlights - Full-year revenue outlook has been upgraded to a growth expectation of 12-14% in local currencies, previously estimated at 9-13% [6][13]. - Tablet sales grew by 16% to DKK 831 million, with Europe and North America showing significant growth rates of 17% and 32%, respectively [6]. - Sales of Other products and services increased by 30% to DKK 215 million, while anaphylaxis revenue surged by 56% [6]. Strategic Initiatives - The launch of new products, including the house dust mite tablet and the neffy adrenaline nasal spray, has exceeded initial market expectations [7][8]. - A dedicated pediatric sales force in the USA has been fully deployed, contributing to growth initiatives [7][8]. - Patient recruitment for the clinical phase 2 trial with the peanut allergy tablet was completed ahead of schedule [7].

Core Insights - Nicox SA announced positive results from the Phase 3 Denali trial for NCX 470, demonstrating non-inferiority in lowering intraocular pressure (IOP) compared to latanoprost [1][4][5] - The trial involved 696 patients and showed IOP reductions of 7.9 to 10.0 mmHg for NCX 470 versus 7.1 to 9.8 mmHg for latanoprost [1][5] - NCX 470 is expected to be submitted for New Drug Applications (NDAs) in the U.S. and China in H1 2026 [4][7] Company Overview - Nicox is an international ophthalmology company focused on innovative solutions for ocular health, with NCX 470 as its lead product candidate [16] - The company has established partnerships with Kowa and Ocumension Therapeutics to facilitate NDA preparations and potential future strategies [7][16] - Nicox's revenue streams include royalties from various products, including ZERVIATE® and VYZULTA® [16] Clinical Trial Details - The Denali trial was a randomized, multi-regional, double-masked study comparing NCX 470 0.1% to latanoprost 0.005% [10][11] - The primary efficacy evaluation was based on IOP reduction at multiple time points, confirming the efficacy profile required for regulatory submissions [11][14] - The trial also included a long-term safety extension, with NCX 470 showing a favorable safety profile [6][11] Financial Implications - Nicox will receive a €5 million milestone payment from Kowa based on the trial results, with potential royalties starting at 8% on net sales in the U.S. [12] - Total potential milestones under the agreement with Kowa are valued at €127 million [12] - Royalties of 6% to 12% on net sales are expected from the Chinese, Korean, and Southeast Asian markets due to the partnership with Ocumension [13]

Core Insights - Multitude Capital Oyj published its Half-Year 2025 Report, highlighting significant financial improvements compared to the previous year [1] Financial Performance - The net interest income for the first half of 2025 was EUR 614 thousand, a substantial increase from a loss of EUR 64 thousand in the same period of 2024 [2][4] - The profit before income tax for H1 2025 was EUR 495 thousand, compared to a loss of EUR 141 thousand in H1 2024 [2] - Net cash flow from operating activities was EUR 1,683 thousand, up from EUR 518 thousand in the previous year [2] Funding Strategy - Multitude Capital Oyj has issued EUR 100 million in senior unsecured bonds under its EUR 150 million bond programme since its inception in June 2024 [3] - The bonds have a floating rate coupon of 3-month EURIBOR plus 6.75% and are listed on the Frankfurt Stock Exchange and Nasdaq Stockholm [3] Financial Position - As of 30 June 2025, total assets amounted to EUR 76.9 million, an increase from EUR 74.7 million at the end of 2024 [5] - Total liabilities were EUR 76.4 million as of 30 June 2025, up from EUR 74.6 million at the end of 2024, primarily due to debt securities issued [5] Company Overview - Multitude Capital Oyj serves as a funding vehicle for Multitude Group, which offers digital lending and online banking services through various business units [6][7] - Multitude Group operates in 25 countries, employing over 700 people and achieving a combined turnover of EUR 264 million in 2024 [7]